Sue Haupt

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8370398/publications.pdf

Version: 2024-02-01

68 papers	3,204 citations	172386 29 h-index	161767 54 g-index
127 all docs	127 docs citations	127 times ranked	5980 citing authors

#	Article	IF	Citations
1	MDM4 is a key therapeutic target in cutaneous melanoma. Nature Medicine, 2012, 18, 1239-1247.	15.2	266
2	Clinical Overview of MDM2/X-Targeted Therapies. Frontiers in Oncology, 2016, 6, 7.	1.3	266
3	Iron accumulation in senescent cells is coupled with impaired ferritinophagy and inhibition of ferroptosis. Redox Biology, 2018, 14, 100-115.	3.9	261
4	Inhibiting the system xCâ˜/glutathione axis selectively targets cancers with mutant-p53 accumulation. Nature Communications, 2017, 8, 14844.	5.8	229
5	Tumour suppression by p53: the importance of apoptosis and cellular senescence. Journal of Pathology, 2009, 219, 3-15.	2.1	156
6	Sex disparities matter in cancer development and therapy. Nature Reviews Cancer, 2021, 21, 393-407.	12.8	136
7	Regulation of nucleotide metabolism by mutant p53 contributes to its gain-of-function activities. Nature Communications, 2015, 6, 7389.	5.8	104
8	E6AP promotes the degradation of the PML tumor suppressor. Cell Death and Differentiation, 2009, 16, 1156-1166.	5.0	88
9	APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma. Gut, 2015, 64, 1506-1516.	6.1	84
10	Regulation of PRMT5â€“MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 17990-18000.	3.3	81
11	Promyelocytic Leukemia Protein is Required for Gain of Function by Mutant p53. Cancer Research, 2009, 69, 4818-4826.	0.4	76
12	Regulation of Mutant p53 Protein Expression. Frontiers in Oncology, 2015, 5, 284.	1.3	69
13	PML enhances the regulation of p53 by CK1 in response to DNA damage. Oncogene, 2008, 27, 3653-3661.	2.6	66
14	Role of p53 in the progression of gastric cancer. Oncotarget, 2014, 5, 12016-12026.	0.8	64
15	The role of MDM2 and MDM4 in breast cancer development and prevention. Journal of Molecular Cell Biology, 2017, 9, 53-61.	1.5	56
16	P53: A Guardian of Immunity Becomes Its Saboteur through Mutation. International Journal of Molecular Sciences, 2020, 21, 3452.	1.8	56
17	C-Abl as a modulator of p53. Biochemical and Biophysical Research Communications, 2005, 331, 737-749.	1.0	54
18	Identification of cancer sex-disparity in the functional integrity of p53 and its X chromosome network. Nature Communications, 2019, 10, 5385.	5.8	53

#	Article	IF	Citations
19	Mdm2 in growth signaling and cancer. Growth Factors, 2005, 23, 183-192.	0.5	52
20	The long and the short of it: the MDM4 tail so far. Journal of Molecular Cell Biology, 2019, 11, 231-244.	1.5	52
21	E6AP ubiquitin ligase regulates PML-induced senescence in Myc-driven lymphomagenesis. Blood, 2012, 120, 822-832.	0.6	50
22	Mutant p53 Drives Cancer by Subverting Multiple Tumor Suppression Pathways. Frontiers in Oncology, 2016, 6, 12.	1.3	49
23	The E3-ligase E6AP Represses Breast Cancer Metastasis via Regulation of ECT2-Rho Signaling. Cancer Research, 2016, 76, 4236-4248.	0.4	45
24	High dose-rate brachytherapy of localized prostate cancer converts tumors from cold to hot. , 2020, 8, e000792.		45
25	Luminal delivery and dosing considerations of local celecoxib administration to colorectal cancer. European Journal of Pharmaceutical Sciences, 2006, 28, 204-211.	1.9	44
26	Targeting Mdmx to treat breast cancers with wild-type p53. Cell Death and Disease, 2015, 6, e1821-e1821.	2.7	37
27	Loss of p53 Causes Stochastic Aberrant X-Chromosome Inactivation and Female-Specific Neural Tube Defects. Cell Reports, 2019, 27, 442-454.e5.	2.9	37
28	MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer. Breast Cancer Research, 2020, 22, 87.	2.2	37
29	Importance of p53 for cancer onset and therapy. Anti-Cancer Drugs, 2006, 17, 725-732.	0.7	36
30	<scp>MDM4</scp> is a rational target for treating breast cancers with mutant p53. Journal of Pathology, 2017, 241, 661-670.	2.1	32
31	The p53-Mdm2 Loop: A Critical Juncture of Stress Response. Sub-Cellular Biochemistry, 2014, 85, 161-186.	1.0	31
32	TP53 Status, Patient Sex, and the Immune Response as Determinants of Lung Cancer Patient Survival. Cancers, 2020, 12, 1535.	1.7	30
33	Clues from worms: a Slug at Puma promotes the survival of blood progenitors. Cell Death and Differentiation, 2006, 13, 913-915.	5.0	25
34	Loss of PML cooperates with mutant p53 to drive more aggressive cancers in a gender-dependent manner. Cell Cycle, 2013, 12, 1722-1731.	1.3	25
35	E6AP promotes prostate cancer by reducing p27 expression. Oncotarget, 2017, 8, 42939-42948.	0.8	25
36	T cell survival and function requires the c-Abl tyrosine kinase. Cell Cycle, 2008, 7, 3847-3857.	1.3	24

#	Article	IF	Citations
37	Reduced abundance of the E3 ubiquitin ligase E6AP contributes to decreased expression of the INK4/ARF locus in nonâ€“small cell lung cancer. Science Signaling, 2017, 10, .	1.6	24
38	SLC7A11 Is a Superior Determinant of APR-246 (Eprenetapopt) Response thanTP53Mutation Status. Molecular Cancer Therapeutics, 2021, 20, 1858-1867.	1.9	24
39	The E6AP E3 ubiquitin ligase regulates the cellular response to oxidative stress. Oncogene, 2013, 32, 3510-3519.	2.6	23
40	c-Abl Phosphorylates E6AP and Regulates Its E3 Ubiquitin Ligase Activity. Biochemistry, 2013, 52, 3119-3129.	1.2	23
41	Expression of E6AP and PML predicts for prostate cancer progression and cancer-specific death. Annals of Oncology, 2014, 25, 2392-2397.	0.6	22
42	A quantitative model to predict pathogenicity of missense variants in the TP53 gene. Human Mutation, 2019, 40, 788-800.	1.1	21
43	p53 controls hPar1 function and expression. Oncogene, 2008, 27, 6866-6874.	2.6	19
44	PML tumour suppression and beyond: Therapeutic implications. FEBS Letters, 2014, 588, 2653-2662.	1.3	18
45	Frequent amplifications of ESR1, ERBB2 and MDM4 in primary invasive lobular breast carcinoma. Cancer Letters, 2019, 461, 21-30.	3.2	18
46	Hhex induces promyelocyte self-renewal and cooperates with growth factor independence to cause myeloid leukemia in mice. Blood Advances, 2018, 2, 347-360.	2.5	16
47	E6AP goes viral: the role of E6AP in viral- and non-viral-related cancers. Carcinogenesis, 2019, 40, 707-714.	1.3	15
48	P53 at the start of the 21st century: lessons from elephants. F1000Research, 2017, 6, 2041.	0.8	15
49	New Strategies to Direct Therapeutic Targeting of PML to Treat Cancers. Frontiers in Oncology, 2013, 3, 124.	1.3	14
50	Proteotranscriptomic Measurements of E6-Associated Protein (E6AP) Targets in DU145 Prostate Cancer Cells. Molecular and Cellular Proteomics, 2018, 17, 1170-1183.	2.5	13
51	p53 Calls upon CIA (Calcium Induced Apoptosis) to Counter Stress. Frontiers in Oncology, 2015, 5, 57.	1.3	12
52	Synchronized release of Doxil and Nutlin-3 by remote degradation of polysaccharide matrices and its possible use in the local treatment of colorectal cancer. Journal of Drug Targeting, 2011, 19, 859-873.	2.1	11
53	E6AP Promotes a Metastatic Phenotype in Prostate Cancer. IScience, 2019, 22, 1-15.	1.9	11
54	Interplay between p53 and VEGF: how to prevent the guardian from becoming a villain. Cell Death and Differentiation, 2013, 20, 852-854.	5.0	10

#	Article	IF	Citations
55	Cancer and Tumour Suppressor p53 Encounters at the Juncture of Sex Disparity. Frontiers in Genetics, 2021, 12, 632719.	1.1	10
56	Immune molecular profiling of a multiresistant primary prostate cancer with a neuroendocrine-like phenotype: a case report. BMC Urology, 2020, 20, 171.	0.6	7
57	Celecoxib can induce cell death independently of cyclooxygenase-2, p53, Mdm2, c-Abl and reactive oxygen species. Anti-Cancer Drugs, 2006, 17, 609-619.	0.7	6
58	Mutant p53 subverts PLK2 function in a novel, reinforced loop of corruption. Cell Cycle, 2012, 11, 217-218.	1.3	6
59	Uncovering a novel pathway for p16 silencing: Therapeutic implications for lung cancer. Molecular and Cellular Oncology, 2017, 4, e1299273.	0.3	6
60	Cannibalism in Breast Cancer: The Dangers of Overeating. Trends in Cancer, 2019, 5, 761-762.	3.8	4
61	Restoring PML tumor suppression to combat cancer. Cell Cycle, 2012, 11, 3705-3706.	1.3	3
62	New insights on the regulation of INK4/ARF locus expression. Oncotarget, 2017, 8, 106147-106148.	0.8	2
63	Direct evidence of a clonal and tumor-directed T cell response to prostate cancer brachytherapy.. Journal of Clinical Oncology, 2019, 37, 22-22.	0.8	1
64	PO-126 Exploration of novel regulators of mutant P53. ESMO Open, 2018, 3, A70.	2.0	0
65	Abstract 4357: Harnessing system xCT- to target mutant p53 cancer cells. , 2016, , .		0
66	New exciting possibilities for the development of precision medicine therapies to restore the expression of the INK4/ARF locus. Annals of Research Hospitals, 0, 1, 1-1.	0.0	0
67	Activation of p53 in combination with endocrine and CDK targeted therapies in ER+ breast cancer. Oncology Abstracts, 0, , .	0.0	0
68	Predicting radiation-induced immune trafficking and activation in localized prostate cancer.. Journal of Clinical Oncology, 2020, 38, 340-340.	0.8	0